SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: squetch who wrote (10481)10/31/1997 2:26:00 AM
From: Andrew H  Read Replies (1) | Respond to of 32384
 
squelchers, want to congratulate you on ferreting out the SRGN drug as the one LGND will choose (if it turns out that way). Still, seems like Targretin is already highly effective for CTCL and the market is pretty small, so I don't see a lot of profit for the drug. Maybe they want to buy out the competition? Of course there is also the lung cancer indication but that is in the future. Sounds like they will not get the psoriasis indication unless they buy the company.

Do you have any thoughts about this? I guess we'll find out more in a couple of weeks. Clearly LGND knows a lot more about the drug than we do.



To: squetch who wrote (10481)10/31/1997 10:20:00 AM
From: Henry Niman  Respond to of 32384
 
Stan, Looks like the big boys are testing the waters. There was a 4K at the full ask, followed by a 5K at the full ask, and then a 10K at the full ask of 15 3/8.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News